UMBRAYA
Allergan Pharmaceuticals International Limited
Mark For: UMBRAYA™ trademark registration is intended to cover the categories of
| Research |
OneLook
Acronym Finder
|
| Serial Number | 88155166 |
| Mark Literal Elements | UMBRAYA |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | TRADEMARK |
| Register | PRINCIPAL |
| Current Location | INTENT TO USE SECTION 2019-10-31 |
| Basis | 1(b) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | Yes |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Matthew O. Brady |
| Law Office Assigned | L40 |
| Employee Name | FATHY, DOMINIC |
Timeline
| 2018-10-15 | Application Filed |
| 2019-03-05 | Published |
| 2019-03-05 | Published for Opposition |
| 2019-10-28 | Status: Live/Pending |
| 2019-10-31 | Location: INTENT TO USE SECTION |
| 2019-10-31 | Transaction Date |
| 2021-03-15 | Status: A fourth request for extension of time to file a Statement of Use has been granted. |
Trademark Parties (Applicants & Owners)
| Party: |  ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED |
| Address | CLONSHAUGH BUSINESS and TECHNOLOGY PARK COOLOCK, DUBLIN IRELAND D17E400 |
| Legal Entity Type | Private Company Limited By Shares (prc) |
| Legal Entity State | IRELAND |
Documents
Drawing
TEAS RF New ApplicationAttorney of Record
Good, Services, and Codes
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2021-03-17 | |
| TEAS EXTENSION RECEIVED | 2021-03-15 | |
| EXTENSION 4 GRANTED | 2021-03-15 | 98765 |
| EXTENSION 4 FILED | 2021-03-15 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-10-06 | |
| TEAS EXTENSION RECEIVED | 2020-10-02 | |
| EXTENSION 3 GRANTED | 2020-10-02 | 98765 |
| EXTENSION 3 FILED | 2020-10-02 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-04-10 | |
| TEAS EXTENSION RECEIVED | 2020-04-08 | |
| EXTENSION 2 GRANTED | 2020-04-08 | 98765 |
| EXTENSION 2 FILED | 2020-04-08 | 98765 |
| EARLY EXTENSION OF USE REFUSED | 2019-10-31 | 69302 |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2019-10-31 | 69302 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-10-30 | |
| TEAS EXTENSION RECEIVED | 2019-10-28 | |
| EXTENSION 1 GRANTED | 2019-10-28 | 98765 |
| EXTENSION 1 FILED | 2019-10-28 | 98765 |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2019-04-30 | |
| PUBLISHED FOR OPPOSITION | 2019-03-05 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-03-05 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-02-13 | |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2019-01-25 | |
| ASSIGNED TO EXAMINER | 2019-01-24 | 81854 |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-10-25 | |
| NEW APPLICATION ENTERED IN TRAM | 2018-10-18 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 